Advertisement

ADVERTISEMENT

Riya Gandhi, MA, Associate Editor

cream
News
Local Tolerability of Topical Roflumilast Across Dermatologic Conditions in Phase 3 Trials
06/25/2024
Riya Gandhi, MA, Associate Editor
Topical roflumilast has demonstrated robust local tolerability profiles in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
Topical roflumilast has demonstrated robust local tolerability profiles in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
Topical roflumilast has...
06/25/2024
The Dermatologist
psoriasis
News
PF-07038124 in Treating Atopic Dermatitis and Plaque Psoriasis
06/24/2024
Riya Gandhi, MA, Associate Editor
In a recent phase 2a clinical trial PF-07038124, a topical phosphodiesterase 4 inhibitor, has shown significant promise in treating both atopic dermatitis and plaque psoriasis, 2 common inflammatory skin conditions known for their challenging...
In a recent phase 2a clinical trial PF-07038124, a topical phosphodiesterase 4 inhibitor, has shown significant promise in treating both atopic dermatitis and plaque psoriasis, 2 common inflammatory skin conditions known for their challenging...
In a recent phase 2a clinical...
06/24/2024
The Dermatologist
telemedicine
News
Dupilumab Demonstrates Efficacy Across All Levels of Prurigo Nodularis Severity: Combined Results from Phase 3 Trials
06/23/2024
Riya Gandhi, MA, Associate Editor
In a comprehensive analysis pooling data from 2 pivotal phase 3 trials, researchers have shown that dupilumab effectively alleviates pruritus and reduces skin lesions in patients with prurigo nodularis, irrespective of the severity of their...
In a comprehensive analysis pooling data from 2 pivotal phase 3 trials, researchers have shown that dupilumab effectively alleviates pruritus and reduces skin lesions in patients with prurigo nodularis, irrespective of the severity of their...
In a comprehensive analysis...
06/23/2024
The Dermatologist
eczema
News
Novel Efficacy Index Compares Long-Term Therapy Outcomes in Atopic Dermatitis Treatments
06/22/2024
Riya Gandhi, MA, Associate Editor
In a new approach to assess long-term treatment outcomes for atopic dermatitis (AD), researchers have introduced a novel efficacy index that accounts for both on-drug and off-drug responses at Week 52.
In a new approach to assess long-term treatment outcomes for atopic dermatitis (AD), researchers have introduced a novel efficacy index that accounts for both on-drug and off-drug responses at Week 52.
In a new approach to assess...
06/22/2024
The Dermatologist
Atopic dermatitis
News
Improving Biomarkers in Atopic Dermatitis: Insights from Lebrikizumab Studies
06/21/2024
Riya Gandhi, MA, Associate Editor
In recent findings from the ADvocate1 and ADvocate2 studies, lebrikizumab has shown promising results in treating moderate-to-severe atopic dermatitis.
In recent findings from the ADvocate1 and ADvocate2 studies, lebrikizumab has shown promising results in treating moderate-to-severe atopic dermatitis.
In recent findings from the...
06/21/2024
The Dermatologist
social media
News
Real-world Insights: Physician-assessed and Patient-reported Outcomes in Atopic Dermatitis Patients Treated with Dupilumab
06/16/2024
Riya Gandhi, MA, Associate Editor
A recent update from the GLOBOSTAD study offered valuable insights into the real-world effectiveness of dupilumab, a promising treatment for atopic dermatitis.
A recent update from the GLOBOSTAD study offered valuable insights into the real-world effectiveness of dupilumab, a promising treatment for atopic dermatitis.
A recent update from the...
06/16/2024
The Dermatologist
AD
FDA Alerts
FDA Approves Tralokinumab Autoinjector for Adults with Moderate-to-Severe Atopic Dermatitis
06/15/2024
Riya Gandhi, MA, Associate Editor
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug...
06/15/2024
The Dermatologist
AD
News
Efficacy of Targeted Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis
06/15/2024
Riya Gandhi, MA, Associate Editor
A recent study, published in SKIN The Journal of Cutaneous Medicine, has compared the efficacy of various targeted systemic monotherapies for moderate-to-severe atopic dermatitis, including the emerging biologic lebrikizumab.
A recent study, published in SKIN The Journal of Cutaneous Medicine, has compared the efficacy of various targeted systemic monotherapies for moderate-to-severe atopic dermatitis, including the emerging biologic lebrikizumab.
A recent study, published in...
06/15/2024
The Dermatologist
medical bill
News
Identifying Candidates for Systemic Therapy in Atopic Dermatitis: A Practical Checklist
06/14/2024
Riya Gandhi, MA, Associate Editor
A novel checklist, known as the, “When to Start Systemic Therapy Checklist,” has been developed to assist dermatology providers in determining when to initiate systemic therapy for patients with atopic dermatitis.
A novel checklist, known as the, “When to Start Systemic Therapy Checklist,” has been developed to assist dermatology providers in determining when to initiate systemic therapy for patients with atopic dermatitis.
A novel checklist, known as the,...
06/14/2024
The Dermatologist
AD
News
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis
06/13/2024
Riya Gandhi, MA, Associate Editor
A recent study has shed light on the efficacy and safety of ruxolitinib cream among adolescents grappling with atopic dermatitis.
A recent study has shed light on the efficacy and safety of ruxolitinib cream among adolescents grappling with atopic dermatitis.
A recent study has shed light on...
06/13/2024
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Psych Congress Regionals
July 18 ⁠–⁠ July 19
Advances in Inflammatory Bowel Disease Regionals
July 19 ⁠–⁠ July 20
July 24 ⁠–⁠ July 26
APP Institute Inflammatory Bowel Disease
July 26 ⁠–⁠ July 27
July 27 ⁠–⁠ July 28
July 27 ⁠–⁠ July 28
Psych Congress Regionals
August 8 ⁠–⁠ August 9
August 14 ⁠–⁠ August 17
APP Institute Dermatology
August 16 ⁠–⁠ August 17
August 16 ⁠–⁠ August 18
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use